Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi

Tropical Medicine and International Health

Volumn 10, Issue 5, 2005, Pages 464-470

  Van Oosterhout, Joep J ^a   Bodasing, Neena ^a,f   Kumwenda, Johnstone J ^a   Nyirenda, Cooper ^a,b   Mallewa, Jane ^a,b   Cleary, Paul R ^a,g   De Baar, Michel P ^c   Schuurman, Rob ^d   Burger, David M ^e   Zijlstra, Eduard E ^a  

^a UNIVERSITY OF MALAWI   (Malawi)

^b QUEEN ELIZABETH CENTRAL HOSPITAL   (Malawi)

^c Primagen   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^g Warrington PCT Headquarters   (United Kingdom)

Author keywords

Adherence; Antiretroviral; HIV; Malawi; Nevirapine

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

DISEASE TREATMENT; DRUG PRESCRIBING;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; ECONOMIC ASPECT; FEMALE; FOLLOW UP; HEADACHE; HELPER CELL; HOSPITAL PHARMACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; LEG PAIN; LIVER TOXICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALAWI; MALE; NAUSEA; PARESTHESIA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PUBLIC HOSPITAL; RASH; SIDE EFFECT; TEACHING HOSPITAL; VIRUS LOAD; VOMITING;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEES AND CHARGES; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALAWI; MALE; MIDDLE AGED; NEVIRAPINE; PATIENT COMPLIANCE; STAVUDINE; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD;

AFRICA; BLANTYRE; EAST AFRICA; EASTERN HEMISPHERE; MALAWI; SUB-SAHARAN AFRICA; WORLD;

EID: 21044451109     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2005.01409.x     Document Type: Article

References (26)

1. Cassol S, Gill MJ, Pilon R, Cormier M, Voight RF, Willoughby B et al. (1997) Quantification of human immunodeficiency virus type 1 RNA from dried plasma spots collected on filter paper. Journal of Clinical Microbiology 35, 2795-2801.
2. Cipla Website (2004) Product information available at: http://www.cipla.com/ourproducts/Antiretrovirals/triomune1.htm. Accessed 13 September 2004.
3. Crowe S, Turnbull S, Oelrichs R & Dunne A (2003) Monitoring of human immunodeficiency virus infection in resource-constrained countries. Clinical Infectious Diseases 37(Suppl. 1), 25-35.
4. de Baar MP, van Dooren MW, de Rooij E, Bakker M, van Gemen B, Goudsmit J et al. (2001) Single rapid real-time monitored isothermal RNA amplification assay for quantification of human immunodeficiency virus type 1 isolates from groups M, N, and O. Journal of Clinical Microbiology 39, 1378-1384.
5. de Baar MP, Timmermans EC, Buitelaar M et al. (2003) Evaluation of the HIV-1 RNA Retina™ rainbow assay on plasma and dried plasma spots: correlation with the Roche Amplicor HIV-1 v1.5 assay [abstract no. 1231]. Presented at: 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France.
6. Department of Health and Human Services (2004) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Available at: http://AIDSinfo.nih.gov. Accessed 13 September 2004.
7. Donnerer J, Kronawetter M, Kapper A, Haas I & Kessler HH (2003) Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir. Pharmacology 69, 197-204.
8. Farmer P, Leandre F, Mukherjee JS, Claude M, Nevil P, Smith-Fawzi MC et al. (2000) Community-based approaches to HIV treatment in resource-poor settings. Lancet 358, 404-409.
9. Harries AD, Nyangulu DS, Hargreaves NJ, Kaluwa O & Salaniponi FM (2001) Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 358, 410-414.
10. Kumarasamy N, Solomon S, Chaguturu SK et al. (2003) The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. AIDS 17, 2267-2269.
11. HIVpharmacology Website (2004) http://www. HIVpharmacology.com. Accessed 13 September 2004.
12. Hollanders RM, Van Ewijk-Beneken Kolmer EW, Burger DM, Wuis EW, Koopmans PP, Hekster YA (2000) Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. Journal of Chromatography B 744, 65-71.
13. Karlsson AC, Younger SR, Martin JN, Grossman Z, Sinclair E, Hunt PW et al. (2004) Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS 18, 981-989.
14. Malawi Ministry of Health and Population Website (2004) Available at: http://www.malawi.gov.mw/health/health2edoc.htm. Accessed 13 September 2004.
15. National Tuberculosis Control Programme, Ministry of Health HIV/AIDS Unit, Department of Clinical Services Ministry of Health, National AIDS Commission (2004) Report of a countrywide survey of HIV/AIDS services in Malawi (for the year 2003), Lilongwe, Malawi.
16. Oliva J, Moreno S, Sanz J, Ribera E, Molina JA, Rubio R et al. (2003) Co-administration of rifampicine and nevirapine in HIV infected patients with tuberculosis. AIDS 17, 637-638.
17. Regazzi M, Villani P, Seminari E, Ravasi G, Cusato M, Marubbi F et al. (2003) Sex differences in nevirapine disposition in HIV-infected patients. AIDS 17, 2399-2400.
18. Ribaudo H, Clifford D, Gulick R, Shikuma C, Klingman K, Snyder S et al. (2004) Relationships between efavirenz pharmacokinetics, side effects, drug discontinuation, virologic response, and race: results from ACTG A5095/A5097s [Abstract 132]. Presented at: 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA.
19. Tassie JM, Szumilin E, Calmy A & Goemaere E (2003) Highly active antiretroviral therapy in resource-poor settings: the experience of Medecins Sans Frontieres. AIDS 17, 1995-1997.
20. Turner BJ (2002) Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. Journal of Infectious Diseases 185(Suppl. 2), S143-S151.
21. Veldkamp AI, Weverling GJ, Lange JM, Montaner JS, Reiss P, Cooper DA et al. (2001) High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 15, 1089-1095.
22. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R et al. (2002) Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 360, 34-40.
23. WHO (2004) Staging System for HIV Infection and Disease in Adults and Adolescents. Available at http://www.who.int/docstore/hiv/scaling/anex1.html. Accessed 13 September 2004.
24. WHO Website (2004). Available at: http://www.who.int/3by5/about/en/. Accessed 13 September 2004.
25. World Health Organisation (2004) Scaling up Antiretroviral Therapy in Resource Poor Settings: Guidelines for a Public Health Approach 2003 Revision. Available at: http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf. Accessed 13 September 2004.
26. Zhou XJ, Sheiner LB, D'Aquila RT, Hughes MD, Hirsch MS, Fischl MA et al. (1999) Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrobial Agents and Chemotherapy 43, 121-128.